Intravesical rad-IFNα/Syn3 for Patients with High-Grade, Bacillus Calmette-Guérin (BCG) Refractory or Relapsed Non-Muscle Invasive Bladder Cancer: A Phase II Randomized Study
Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd–IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC.
Read more ...
